Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2012American Journal of TransplantationOpen Access

Risk Factors for Voriconazole Hepatotoxicity at 12 Weeks in Lung Transplant Recipients

View Full Paper
Ask AI
Bookmark
Share

Authors

MLM-L. LuongSHSeyed M. Hosseini‐MoghaddamWestern UniversityLSL.G. SingerUniversity Health Network

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Luong et al. (2012) studied this question.

synapsesocial.com/papers/6a85c676734852141cd4e009https://doi.org/10.1111/j.1600-6143.2012.04042.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome2002 · 253 citations
  2. 2Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients2011 · 66 citations
  3. 3Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes2007 · 892 citations
  4. 4Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients2011 · 218 citations
  5. 5Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms2007 · 85 citations